

# FDA TALK PAPER

FOOD AND DRUG ADMINISTRATION  
U.S. Department of Health and Human Services  
Public Health Service 5600 Fishers Lane Rockville, Maryland 20857

FDA Talk Papers are prepared by the Press Office to guide FDA personnel in responding with consistency and accuracy to questions from the public on subjects of current interest. Talk Papers are subject to change as more information becomes available. Talk Papers are not intended for general distribution outside FDA, but all information in them is public, and full texts are releasable upon request.

T87-7  
Jan. 29, 1987

Brad Stone  
(301) 443-3285

## FDA ISSUES ALERT AGAINST DANGEROUS DRUGS FROM "HAUPTMANN INSTITUTE"

FDA has issued an Import Alert to halt the importation of a variety of prescription drugs distributed by the "Hauptmann Institute" of Vienna, Austria, because they are sold directly to the public and lack adequate directions for use. In some cases, these drugs could be potentially lethal if not taken under the supervision of a physician.

Among the drugs distributed by Hauptmann are those with extremely dangerous side effects such as dementia, life-threatening blood disorders, liver damage, hypotension, and congestive heart failure. FDA and the Postal Service have learned that solicitations and price lists for Hauptmann products are mailed from several points within the United States and Canada, orders are sent to Vienna, Austria, and all shipments have been made from Luton, England.

Although several of the drugs distributed by Hauptmann have domestic approval for specific indications, all of the products are misbranded and include unapproved indications for use. Other drugs sold by Hauptmann are unapproved in the United States for any indication.

In order to protect the public from exposure to these dangerously misbranded unapproved drugs, FDA's Import Alert requests the Postal Service and the Customs Service to detain all quantities of these products that are being brought into the United States.

#####